Dose-response curves for Drug: Ifosfamide 100 -CellLine JHU 2-002 JHU 2-002 CL JHU 2-031 JHU 2-079 JHU 2-103 75 MN1 MN2 MN3-001 MN3-002 WU-225 Viabilities % WU-356 50 Temp JHU 2-002 JHU 2-002 CL - JHU 2-031 JHU 2-079 25 JHU 2-103 MN1 MN2 MN3-001 MN3-002 WU-225 WU-356 0 -

-5


Conc log(M)


-3


_7


-6

Dose-response curves for Drug: Irinotecan 100 -Temp JHU 2-002 JHU 2-002 CL JHU 2-031 JHU 2-079 JHU 2-103 75 -MN1 MN2 MN3-001 MN3-002 Viabilities % WU-225 50 CellLine JHU 2-002 JHU 2-002 CL JHU 2-031 JHU 2-079 JHU 2-103 25 MN1 MN2 MN3-001 MN3-002 WU-225 0 -5 _7 -6 -3 Conc log(M)













Dose-response curves for Drug: Sapanisertib 100 -CellLine JHU 2-002 JHU 2-002 CL JHU 2-031 JHU 2-079 JHU 2-103 75 MN1 MN2 MN3-001 MN3-002 ST88-14 Viabilities % WU-225 50 Temp JHU 2-002 JHU 2-002 CL JHU 2-031 JHU 2-079 25 JHU 2-103 MN1 MN2 MN3-001 MN3-002 ST88-14 0 WU-225 <u>-</u>7 -6 -5 -3 Conc log(M)







Dose-response curves for Drug: Sirolimus CellLine 100 -JHU 2-002 JHU 2-031 JHU 2-079 JHU 2-103 MN1 75 -MN2 MN3-001 MN3-002 WU-225 Viabilities % WU-368 50 Temp JHU 2-002 JHU 2-031 JHU 2-079 JHU 2-103 MN1 25 MN2 MN3-001 MN3-002 WU-225 WU-368 0 <u>-</u>7 -6 <u>-</u>5 -3 Conc log(M)









Dose-response curves for Drug: Bortezomib CellLine 100 JHU 2-002 JHU 2-002 CL JHU 2-031 JHU 2-079 JHU 2-103 MN1 75 MN2 MN3-001 MN3-002 WU-225 Viabilities % WU-356 50 Temp JHU 2-002 JHU 2-002 CL - JHU 2-031 - JHU 2-079 25 JHU 2-103 MN1 MN2 MN3-001 MN3-002 WU-225 0 WU-356 -8 -6


Conc log(M)

Dose-response curves for Drug: Brigatinib CellLine JHU 2-002 100 JHU 2-002 CL JHU 2-031 JHU 2-079 JHU 2-103 MN1 MN2 75 · MN3-001 MN3-002 WU-225 Viabilities % WU-356 Temp 50 JHU 2-002 JHU 2-002 CL - JHU 2-031 - JHU 2-079 JHU 2-103 MN1 MN2 25 MN3-001 MN3-002 WU-225 WU-356 <u>-</u>9 -8 _7 -6 -5 Conc log(M)

Dose-response curves for Drug: Cabozantinib 100 CellLine JHU 2-002 JHU 2-031 JHU 2-079 JHU 2-103 75 MN1 MN2 MN3-001 MN3-002 WU-225 Viabilities % WU-368 50 Temp JHU 2-002 JHU 2-031 JHU 2-079 JHU 2-103 MN1 25 MN2 MN3-001 MN3-002 WU-225 WU-368 0 <u>-</u>5 5 Conc log(M)

Dose-response curves for Drug: Carboplatin 100 CellLine JHU 2-002 JHU 2-031 JHU 2-079 JHU 2-103 MN1 75 MN2 MN3-001 MN3-002 WU-225 Viabilities % WU-368 50 Temp JHU 2-002 JHU 2-031 JHU 2-079 JHU 2-103 25 MN1 MN2 MN3-001 MN3-002 WU-225 WU-368 0 _7 -6 -5 Conc log(M)


Dose-response curves for Drug: Cerdulatinib 100 CellLine JHU 2-002 JHU 2-031 JHU 2-079 JHU 2-103 MN1 75 MN2 MN3-001 MN3-002 WU-225 Viabilities % WU-368 50 -Temp JHU 2-002 JHU 2-031 JHU 2-079 25 JHU 2-103 MN1 MN2 MN3-001 MN3-002 WU-225 0 WU-368 -5 5 Conc log(M)



Dose-response curves for Drug: Dacarbazine CellLine 100 -JHU 2-002 JHU 2-002 CL JHU 2-031 JHU 2-079 JHU 2-103 MN1 75 MN2 MN3-001 MN3-002 WU-225 Viabilities % WU-356 50 Temp - JHU 2-002 JHU 2-002 CL - JHU 2-031 - JHU 2-079 JHU 2-103 25 MN1 MN2 MN3-001 MN3-002 WU-225 WU-356 0 -8 -7 -6 -5

Conc log(M)


Dose-response curves for Drug: Digoxin Temp 100 JHU 2-002 JHU 2-031 JHU 2-079 JHU 2-103 MN1 MN2 75 MN3-001 MN3-002 ST88-14 WU-225 Viabilities % WU-368 50 -CellLine JHU 2-002 JHU 2-031 JHU 2-079 JHU 2-103 MN1 25 MN2 MN3-001 MN3-002 ST88-14 WU-225 WU-368 0 -8 _₇ -5 Conc log(M)



Dose-response curves for Drug: Epirubicin Temp 100 -JHU 2-002 JHU 2-002 CL - JHU 2-031 JHU 2-079 JHU 2-103 MN1 75 MN2 MN3-001 MN3-002 Viabilities % WU-225 50 CellLine JHU 2-002 JHU 2-002 CL JHU 2-031 JHU 2-079 JHU 2-103 25 · MN1 MN2 MN3-001 MN3-002 WU-225 0 -8 <u>-</u>7 -6 -5 -4Conc log(M)


Dose-response curves for Drug: Eribulin CellLine 100 JHU 2-002 JHU 2-002 CL JHU 2-031 JHU 2-079 JHU 2-103 MN1 75 -MN2 MN3-001 MN3-002 WU-225 Viabilities % WU-356 50 -Temp - JHU 2-002 - JHU 2-002 CL - JHU 2-031 - JHU 2-079 JHU 2-103 25 MN1 MN2 MN3-001 MN3-002 WU-225 WU-356 0 -9 -8 -6 -7 Conc log(M)

Dose-response curves for Drug: Erlotinib 100 -CellLine JHU 2-002 JHU 2-031 JHU 2-079 JHU 2-103 MN1 75 MN2 MN3-001 MN3-002 WU-225 Viabilities % WU-368 50 Temp JHU 2-002 JHU 2-031 JHU 2-079 JHU 2-103 MN1 25 MN2 MN3-001 MN3-002 WU-225 WU-368 -5 5 Conc log(M)



Dose-response curves for Drug: Selumetinib; Vorinostat 100 CellLine JHU 2-002 JHU 2-002 CL JHU 2-031 JHU 2-079 CL 75 -MN1 MN2 MN3-001 WU-225 Viabilities % WU-356 50 Temp JHU 2-002 JHU 2-002 CL JHU 2-031 JHU 2-079 CL 25 MN1 MN2 MN3-001 WU-225 WU-356 0 <u>-</u>7 <u>-</u>5 -6 Conc log(M)

Dose-response curves for Drug: SHP099;Ribociclib 100 CellLine JHU 2-002 JHU 2-002 CL JHU 2-031 JHU 2-079 CL 75 · MN1 MN2 MN3-001 WU-225 Viabilities % WU-356 50 Temp JHU 2-002 JHU 2-002 CL JHU 2-031 JHU 2-079 CL MN1 25 MN2 MN3-001 WU-225 WU-356 -5 -8 _7 -6 -4 Conc log(M)



Dose-response curves for Drug: Olaparib; Trabectedin 100 CellLine JHU 2-002 JHU 2-002 CL JHU 2-031 JHU 2-079 CL 75 MN1 MN2 MN3-001 WU-225 Viabilities % WU-356 50 Temp JHU 2-002 JHU 2-002 CL JHU 2-031 JHU 2-079 CL 25 MN1 MN2 MN3-001 WU-225 WU-356 0 <u>-</u>7 -9 -8 -6 -5 Conc log(M)

Dose-response curves for Drug: Trametinib; Ribociclib 100 Temp JHU 2-002 CL JHU 2-079 CL 75 MN1 MN2 MN3-001 WU-225 Viabilities % WU-356 50 -CellLine JHU 2-002 CL JHU 2-079 CL MN1 MN2 25 MN3-001 WU-225 WU-356 0 -6 <u>-</u>9 -8 _7 -5 Conc log(M)

Dose-response curves for Drug: Mirdametinib; Trabectedin 100 Temp JHU 2-002 75 JHU 2-031 JHU 2-079 CL MN1 MN2 MN3-001 Viabilities % WU-225 50 -CellLine JHU 2-002 JHU 2-031 JHU 2-079 CL MN1 25 MN2 MN3-001 WU-225 0 -7 -5 <u>-</u>9 -8 -6 Conc log(M)

